Navigation Links
Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
Date:1/25/2009

180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months

SAN DIEGO, Jan. 26 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the completion of enrollment in its randomized, double-blind Phase 2 clinical trial testing the oral dosage form of torezolid (also known as TR-701) in patients with complicated skin and skin structure infections (cSSSI). The trial, which was conducted in 12 clinical sites in the United States, examined the efficacy and safety of three dosage strengths of torezolid administered orally once daily over a 5-7 day course of treatment. Top line results of the Phase 2 trial are expected in the second quarter of this year.

"The rapid enrollment in this trial is not only a testimony to the diligence and competence of our clinical investigators and colleagues, but is also an indicator of the increasing prevalence of bacterial infections caused by MRSA in our hospitals and communities and the potential for an oral drug to confront this epidemic," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "Over 90% of the pathogens infecting patients enrolled in our Phase 2 trial were Staphylococcus aureus, of which nearly 70% were MRSA. Oral torezolid appears well tolerated and effective as a once-daily therapy to quickly eradicate MRSA and other Gram-positive bacteria causing complicated skin infections."

"Having initiated Phase 1 testing of torezolid in January of 2008, it is very encouraging to have advanced the program through Phase 2 enrollment in approximately one year," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We aim to continue this momentum and advance the intravenous dosage form of torezolid through Phase 1 testing this year and to initiate Phase 3 testing of both the intravenous and oral dosage forms shortly thereafter. Our goal is to offer patients and physicians a 'best-in-class' therapeutic option to address the growing unmet need for safe and effective treatments for drug resistant bacterial infections in the hospital and in the community."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Bluestar Silicones ... (LSR) product line for long-term implant applications and ... Medical Design & Manufacturing (MD&M) West Conference (Booth ... --> --> ... Silbione® Biomedical LSRs offer outstanding physical properties enabling ...
(Date:2/8/2016)... , Feb.8, 2016 Respiratory Devices - ... GlobalData,s Medical Devices sector report, " Respiratory Devices ... an overview of Respiratory Devices currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG Technologies, ... PW Series Solvent Recycling Systems, specifically designed for ... integration with new and existing vapor degreasers, parts ... consistently-fresh solvent through continuous recycling and recovers 100% ... --> --> Precision parts manufacturers ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Sir ... company , is proud to announce that many of their franchises have received ... service. The hard surface restoration franchises received customer recognition through positive reviews and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... CURE ... patients, has officially launched the Multiple Myeloma Heroes Awards event , which will ... in the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):